Search hospitals

>

Alabama

>

Birmingham

University of Alabama at Birmingham

Claim this profile

Birmingham, Alabama 35205

Global Leader in Cancer

Global Leader in Breast Cancer

Conducts research for HIV Infection

Conducts research for Human Immunodeficiency Virus Infection

Conducts research for Cystic Fibrosis

2622 reported clinical trials

273 medical researchers

Photo of University of Alabama at Birmingham in BirminghamPhoto of University of Alabama at Birmingham in Birmingham

Summary

University of Alabama at Birmingham is a medical facility located in Birmingham, Alabama. This center is recognized for care of Cancer, Breast Cancer, HIV Infection, Human Immunodeficiency Virus Infection, Cystic Fibrosis and other specialties. University of Alabama at Birmingham is involved with conducting 2,622 clinical trials across 2,255 conditions. There are 273 research doctors associated with this hospital, such as Mustafa Ahmed, MD, Girish Dhall, MD, Rebecca C. Arend, and Jonathan McConathy, MD, PhD.

Area of expertise

1

Cancer

Global Leader

University of Alabama at Birmingham has run 123 trials for Cancer. Some of their research focus areas include:

Stage IV
HER2 positive
Stage III
2

Breast Cancer

Global Leader

University of Alabama at Birmingham has run 119 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
HER2 positive
Stage III

Top PIs

Clinical Trials running at University of Alabama at Birmingham

Multiple Myeloma

Rheumatoid Arthritis

Gout

Sickle Cell Disease

Multiple Sclerosis

Urinary Incontinence

Pre-eclampsia

Cancer

Premature Birth

Sepsis

Image of trial facility.

Iberdomide Combo

for Multiple Myeloma

Similar to the paradigm established in other hematologic malignancies that are considered curable, the achievement of MRD(-) status is necessary for long term disease control in MM. The fact that the majority of patients remain MRD (+) after induction therapy and AHCT points to the opportunity to deploy novel agents with complementary mechanism of action and favorable toxicity profile to reach and maintain MRD (-) status. Given its favorable toxicity profile, the convenience of oral administration, and compelling single agent activity even in heavily pretreated MM, iberdomide is likely amenable to long term therapy in patients with high-risk of relapse/progression identified by the persistence of MRD(+). The investigators intend to develop combination(s) of iberdomide with other agents with complementary mechanism of action in the consolidation setting post AHCT in order to achieve and sustain MRD (-).

Recruiting

3 awards

Phase 1 & 2

14 criteria

Image of trial facility.

DaraVRD

for Multiple Myeloma

This trial uses a high-tech test to check for tiny amounts of leftover cancer cells in patients with newly diagnosed multiple myeloma. If no cancer cells are found, doctors might delay a major treatment called stem cell transplant. This approach aims to avoid the severe side effects of the transplant if it's not needed.

Recruiting

3 awards

Phase 2

9 criteria

Image of trial facility.

BMS-986393

for Multiple Myeloma

The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.

Recruiting

2 awards

Phase 3

3 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University of Alabama at Birmingham?

Where is University of Alabama at Birmingham located?

Who should I call to ask about financial aid or insurance network?

What insurance does University of Alabama at Birmingham accept?

What awards or recognition has University of Alabama at Birmingham received?